Your browser doesn't support javascript.
loading
Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting.
Kapniari, Eirini; Dalamaga, Maria; Papadavid, Evangelia.
Afiliação
  • Kapniari E; Second Department of Dermatology and Venereology, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Dalamaga M; Second Department of Dermatology and Venereology, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Papadavid E; Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Dermatol Ther ; 33(6): e14168, 2020 11.
Article em En | MEDLINE | ID: mdl-32779293

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Preparações Farmacêuticas Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Dermatol Ther Assunto da revista: DERMATOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Grécia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Preparações Farmacêuticas Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Dermatol Ther Assunto da revista: DERMATOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Grécia